{'fraction_non_alphanumeric': 0.02050326188257223, 'fraction_numerical': 0.0027958993476234857, 'mean_word_length': 5.670807453416149, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The evolving model of care for familial hypercholesterolaemia

The exponential growth in scientific publications and major guidelines over the last 6 years on familial hypercholesterolaemia (FH) underscores the evolving importance of this condition in preventative cardiology. Ultimately, these works aim to improve outcomes for patients and families by enhancing existing models of care for FH. The typical model of care for FH has several components: screening and detection of cases; use of diagnostic tools including genetic testing; risk stratification of cases; definition of low-density lipoprotein (LDL) cholesterol targets and their attainment with therapies; organisation of services; utilisation of patient networks and advocacy groups; disease c1odification and registries; development of research programs that can feedback on care. The review by Pećin et al. summarises recent advances in the management of FH, with a focus on PCSK9 inhibitors that inform evolving models of care. However, certain aspects need underscoring to draw attention to evidence gaps.